A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali.
Identifieur interne : 001B51 ( PubMed/Curation ); précédent : 001B50; suivant : 001B52A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali.
Auteurs : Yaya Ibrahim Coulibaly [Mali] ; Ilo Dicko ; Modibo Keita ; Mahamadou Minamba Keita ; Moussa Doumbia ; Adama Daou ; Fadima Cheick Haidara ; Moussa Hama Sankare ; John Horton ; Caroline Whately-Smith ; Samba Ousmane SowSource :
- PLoS neglected tropical diseases [ 1935-2735 ] ; 2013.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Albendazole (effets indésirables), Albendazole (usage thérapeutique), Antibactériens (effets indésirables), Antibactériens (usage thérapeutique), Antihelminthiques (effets indésirables), Antihelminthiques (usage thérapeutique), Association de médicaments (), Association de médicaments (effets indésirables), Azithromycine (effets indésirables), Azithromycine (usage thérapeutique), Chimioprévention (), Chimioprévention (effets indésirables), Co-infection (), Co-infection (traitement médicamenteux), Effets secondaires indésirables des médicaments (anatomopathologie), Effets secondaires indésirables des médicaments (épidémiologie), Enfant, Enfant d'âge préscolaire, Femelle, Filariose lymphatique (), Filariose lymphatique (traitement médicamenteux), Humains, Ivermectine (effets indésirables), Ivermectine (usage thérapeutique), Jeune adulte, Maladies négligées (), Maladies négligées (traitement médicamenteux), Mali, Mâle, Sujet âgé, Trachome (), Trachome (traitement médicamenteux).
- MESH :
- anatomopathologie : Effets secondaires indésirables des médicaments.
- effets indésirables : Albendazole, Antibactériens, Antihelminthiques, Association de médicaments, Azithromycine, Chimioprévention, Ivermectine.
- traitement médicamenteux : Co-infection, Filariose lymphatique, Maladies négligées, Trachome.
- usage thérapeutique : Albendazole, Antibactériens, Antihelminthiques, Azithromycine, Ivermectine.
- épidémiologie : Effets secondaires indésirables des médicaments.
- Adolescent, Adulte, Adulte d'âge moyen, Association de médicaments, Chimioprévention, Co-infection, Enfant, Enfant d'âge préscolaire, Femelle, Filariose lymphatique, Humains, Jeune adulte, Maladies négligées, Mali, Mâle, Sujet âgé, Trachome.
- Wicri :
- geographic : Mali.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Albendazole (adverse effects), Albendazole (therapeutic use), Anthelmintics (adverse effects), Anthelmintics (therapeutic use), Anti-Bacterial Agents (adverse effects), Anti-Bacterial Agents (therapeutic use), Azithromycin (adverse effects), Azithromycin (therapeutic use), Chemoprevention (adverse effects), Chemoprevention (methods), Child, Child, Preschool, Coinfection (drug therapy), Coinfection (prevention & control), Drug Therapy, Combination (adverse effects), Drug Therapy, Combination (methods), Drug-Related Side Effects and Adverse Reactions (epidemiology), Drug-Related Side Effects and Adverse Reactions (pathology), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (prevention & control), Female, Humans, Ivermectin (adverse effects), Ivermectin (therapeutic use), Male, Mali, Middle Aged, Neglected Diseases (drug therapy), Neglected Diseases (prevention & control), Trachoma (drug therapy), Trachoma (prevention & control), Young Adult.
- MESH :
- chemical , adverse effects : Albendazole, Anthelmintics, Anti-Bacterial Agents, Azithromycin, Ivermectin.
- chemical , therapeutic use : Albendazole, Anthelmintics, Anti-Bacterial Agents, Azithromycin, Ivermectin.
- geographic : Mali.
- adverse effects : Chemoprevention, Drug Therapy, Combination.
- drug therapy : Coinfection, Elephantiasis, Filarial, Neglected Diseases, Trachoma.
- epidemiology : Drug-Related Side Effects and Adverse Reactions.
- methods : Chemoprevention, Drug Therapy, Combination.
- pathology : Drug-Related Side Effects and Adverse Reactions.
- prevention & control : Coinfection, Elephantiasis, Filarial, Neglected Diseases, Trachoma.
- Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Male, Middle Aged, Young Adult.
Abstract
Neglected tropical diseases are co-endemic in many areas of the world, including sub Saharan Africa. Currently lymphatic filariasis (albendazole/ivermectin) and trachoma (azithromycin) are treated separately. Consequently, financial and logistical benefit can be gained from integration of preventive chemotherapy programs in such areas.
DOI: 10.1371/journal.pntd.0002221
PubMed: 23675549
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001B51
Links to Exploration step
pubmed:23675549Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali.</title><author><name sortKey="Coulibaly, Yaya Ibrahim" sort="Coulibaly, Yaya Ibrahim" uniqKey="Coulibaly Y" first="Yaya Ibrahim" last="Coulibaly">Yaya Ibrahim Coulibaly</name><affiliation wicri:level="1"><nlm:affiliation>Centre National d'Appui à la Lutte contre la Maladie, Bamako, Mali.</nlm:affiliation><country xml:lang="fr">Mali</country><wicri:regionArea>Centre National d'Appui à la Lutte contre la Maladie, Bamako</wicri:regionArea></affiliation></author><author><name sortKey="Dicko, Ilo" sort="Dicko, Ilo" uniqKey="Dicko I" first="Ilo" last="Dicko">Ilo Dicko</name></author><author><name sortKey="Keita, Modibo" sort="Keita, Modibo" uniqKey="Keita M" first="Modibo" last="Keita">Modibo Keita</name></author><author><name sortKey="Keita, Mahamadou Minamba" sort="Keita, Mahamadou Minamba" uniqKey="Keita M" first="Mahamadou Minamba" last="Keita">Mahamadou Minamba Keita</name></author><author><name sortKey="Doumbia, Moussa" sort="Doumbia, Moussa" uniqKey="Doumbia M" first="Moussa" last="Doumbia">Moussa Doumbia</name></author><author><name sortKey="Daou, Adama" sort="Daou, Adama" uniqKey="Daou A" first="Adama" last="Daou">Adama Daou</name></author><author><name sortKey="Haidara, Fadima Cheick" sort="Haidara, Fadima Cheick" uniqKey="Haidara F" first="Fadima Cheick" last="Haidara">Fadima Cheick Haidara</name></author><author><name sortKey="Sankare, Moussa Hama" sort="Sankare, Moussa Hama" uniqKey="Sankare M" first="Moussa Hama" last="Sankare">Moussa Hama Sankare</name></author><author><name sortKey="Horton, John" sort="Horton, John" uniqKey="Horton J" first="John" last="Horton">John Horton</name></author><author><name sortKey="Whately Smith, Caroline" sort="Whately Smith, Caroline" uniqKey="Whately Smith C" first="Caroline" last="Whately-Smith">Caroline Whately-Smith</name></author><author><name sortKey="Sow, Samba Ousmane" sort="Sow, Samba Ousmane" uniqKey="Sow S" first="Samba Ousmane" last="Sow">Samba Ousmane Sow</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23675549</idno><idno type="pmid">23675549</idno><idno type="doi">10.1371/journal.pntd.0002221</idno><idno type="wicri:Area/PubMed/Corpus">001B51</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B51</idno><idno type="wicri:Area/PubMed/Curation">001B51</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B51</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali.</title><author><name sortKey="Coulibaly, Yaya Ibrahim" sort="Coulibaly, Yaya Ibrahim" uniqKey="Coulibaly Y" first="Yaya Ibrahim" last="Coulibaly">Yaya Ibrahim Coulibaly</name><affiliation wicri:level="1"><nlm:affiliation>Centre National d'Appui à la Lutte contre la Maladie, Bamako, Mali.</nlm:affiliation><country xml:lang="fr">Mali</country><wicri:regionArea>Centre National d'Appui à la Lutte contre la Maladie, Bamako</wicri:regionArea></affiliation></author><author><name sortKey="Dicko, Ilo" sort="Dicko, Ilo" uniqKey="Dicko I" first="Ilo" last="Dicko">Ilo Dicko</name></author><author><name sortKey="Keita, Modibo" sort="Keita, Modibo" uniqKey="Keita M" first="Modibo" last="Keita">Modibo Keita</name></author><author><name sortKey="Keita, Mahamadou Minamba" sort="Keita, Mahamadou Minamba" uniqKey="Keita M" first="Mahamadou Minamba" last="Keita">Mahamadou Minamba Keita</name></author><author><name sortKey="Doumbia, Moussa" sort="Doumbia, Moussa" uniqKey="Doumbia M" first="Moussa" last="Doumbia">Moussa Doumbia</name></author><author><name sortKey="Daou, Adama" sort="Daou, Adama" uniqKey="Daou A" first="Adama" last="Daou">Adama Daou</name></author><author><name sortKey="Haidara, Fadima Cheick" sort="Haidara, Fadima Cheick" uniqKey="Haidara F" first="Fadima Cheick" last="Haidara">Fadima Cheick Haidara</name></author><author><name sortKey="Sankare, Moussa Hama" sort="Sankare, Moussa Hama" uniqKey="Sankare M" first="Moussa Hama" last="Sankare">Moussa Hama Sankare</name></author><author><name sortKey="Horton, John" sort="Horton, John" uniqKey="Horton J" first="John" last="Horton">John Horton</name></author><author><name sortKey="Whately Smith, Caroline" sort="Whately Smith, Caroline" uniqKey="Whately Smith C" first="Caroline" last="Whately-Smith">Caroline Whately-Smith</name></author><author><name sortKey="Sow, Samba Ousmane" sort="Sow, Samba Ousmane" uniqKey="Sow S" first="Samba Ousmane" last="Sow">Samba Ousmane Sow</name></author></analytic><series><title level="j">PLoS neglected tropical diseases</title><idno type="eISSN">1935-2735</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Albendazole (adverse effects)</term><term>Albendazole (therapeutic use)</term><term>Anthelmintics (adverse effects)</term><term>Anthelmintics (therapeutic use)</term><term>Anti-Bacterial Agents (adverse effects)</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Azithromycin (adverse effects)</term><term>Azithromycin (therapeutic use)</term><term>Chemoprevention (adverse effects)</term><term>Chemoprevention (methods)</term><term>Child</term><term>Child, Preschool</term><term>Coinfection (drug therapy)</term><term>Coinfection (prevention & control)</term><term>Drug Therapy, Combination (adverse effects)</term><term>Drug Therapy, Combination (methods)</term><term>Drug-Related Side Effects and Adverse Reactions (epidemiology)</term><term>Drug-Related Side Effects and Adverse Reactions (pathology)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Female</term><term>Humans</term><term>Ivermectin (adverse effects)</term><term>Ivermectin (therapeutic use)</term><term>Male</term><term>Mali</term><term>Middle Aged</term><term>Neglected Diseases (drug therapy)</term><term>Neglected Diseases (prevention & control)</term><term>Trachoma (drug therapy)</term><term>Trachoma (prevention & control)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Albendazole (effets indésirables)</term><term>Albendazole (usage thérapeutique)</term><term>Antibactériens (effets indésirables)</term><term>Antibactériens (usage thérapeutique)</term><term>Antihelminthiques (effets indésirables)</term><term>Antihelminthiques (usage thérapeutique)</term><term>Association de médicaments ()</term><term>Association de médicaments (effets indésirables)</term><term>Azithromycine (effets indésirables)</term><term>Azithromycine (usage thérapeutique)</term><term>Chimioprévention ()</term><term>Chimioprévention (effets indésirables)</term><term>Co-infection ()</term><term>Co-infection (traitement médicamenteux)</term><term>Effets secondaires indésirables des médicaments (anatomopathologie)</term><term>Effets secondaires indésirables des médicaments (épidémiologie)</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Humains</term><term>Ivermectine (effets indésirables)</term><term>Ivermectine (usage thérapeutique)</term><term>Jeune adulte</term><term>Maladies négligées ()</term><term>Maladies négligées (traitement médicamenteux)</term><term>Mali</term><term>Mâle</term><term>Sujet âgé</term><term>Trachome ()</term><term>Trachome (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Anti-Bacterial Agents</term><term>Azithromycin</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Anti-Bacterial Agents</term><term>Azithromycin</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Mali</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Chemoprevention</term><term>Drug Therapy, Combination</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coinfection</term><term>Elephantiasis, Filarial</term><term>Neglected Diseases</term><term>Trachoma</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Albendazole</term><term>Antibactériens</term><term>Antihelminthiques</term><term>Association de médicaments</term><term>Azithromycine</term><term>Chimioprévention</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Chemoprevention</term><term>Drug Therapy, Combination</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coinfection</term><term>Elephantiasis, Filarial</term><term>Neglected Diseases</term><term>Trachoma</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Co-infection</term><term>Filariose lymphatique</term><term>Maladies négligées</term><term>Trachome</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Antibactériens</term><term>Antihelminthiques</term><term>Azithromycine</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association de médicaments</term><term>Chimioprévention</term><term>Co-infection</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Filariose lymphatique</term><term>Humains</term><term>Jeune adulte</term><term>Maladies négligées</term><term>Mali</term><term>Mâle</term><term>Sujet âgé</term><term>Trachome</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Mali</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Neglected tropical diseases are co-endemic in many areas of the world, including sub Saharan Africa. Currently lymphatic filariasis (albendazole/ivermectin) and trachoma (azithromycin) are treated separately. Consequently, financial and logistical benefit can be gained from integration of preventive chemotherapy programs in such areas.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23675549</PMID><DateCreated><Year>2013</Year><Month>05</Month><Day>15</Day></DateCreated><DateCompleted><Year>2013</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1935-2735</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>5</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>PLoS neglected tropical diseases</Title><ISOAbbreviation>PLoS Negl Trop Dis</ISOAbbreviation></Journal><ArticleTitle>A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali.</ArticleTitle><Pagination><MedlinePgn>e2221</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pntd.0002221</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neglected tropical diseases are co-endemic in many areas of the world, including sub Saharan Africa. Currently lymphatic filariasis (albendazole/ivermectin) and trachoma (azithromycin) are treated separately. Consequently, financial and logistical benefit can be gained from integration of preventive chemotherapy programs in such areas.</AbstractText><AbstractText Label="METHODOLOGY/FINDINGS" NlmCategory="RESULTS">4 villages in two co-endemic districts (Kolondièba and Bougouni) of Sikasso, Mali, were randomly assigned to coadministered treatment (ivermectin/albendazole/azithromycin) or standard therapy (ivermectin/albendazole with azithromycin 1 week later). These villages had previously undergone 4 annual MDA campaigns with ivermectin/albendazole and 2 with azithromycin. One village was randomly assigned to each treatment arm in each district. There were 7515 eligible individuals in the 4 villages, 3011(40.1%) of whom participated in the study. No serious adverse events occurred, and the majority of adverse events were mild in intensity (mainly headache, abdominal pain, diarrhoea and "other signs/symptoms"). The median time to the onset of the first event, of any type, was later (8 days) in the two standard treatment villages than in the co-administration villages. Overall the number of subjects reporting any event was similar in the co-administration group compared to the standard treatment group [18.7% (281/1501) vs. 15.8% (239/1510)]. However, the event frequency was higher in the coadministration group (30.4%) than in the standard treatment group (11.0%) in Kolondièba, while the opposite was observed in Bougouni (7.1% and 20.9% respectively). Additionally, the overall frequency of adverse events in the co-administration group (18.7%) was comparable to or lower than published frequencies for ivermectin+albendazole alone.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data suggest that co-administration of ivermectin+albendazole and azithromycin is safe; however the small number of villages studied and the large differences between them resulted in an inability to calculate a meaningful overall estimate of the difference in adverse event rates between the regimens. Further work is therefore needed before co-administration can be definitively recommended.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov; NCT01586169.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coulibaly</LastName><ForeName>Yaya Ibrahim</ForeName><Initials>YI</Initials><AffiliationInfo><Affiliation>Centre National d'Appui à la Lutte contre la Maladie, Bamako, Mali.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dicko</LastName><ForeName>Ilo</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Keita</LastName><ForeName>Modibo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Keita</LastName><ForeName>Mahamadou Minamba</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Doumbia</LastName><ForeName>Moussa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Daou</LastName><ForeName>Adama</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Haidara</LastName><ForeName>Fadima Cheick</ForeName><Initials>FC</Initials></Author><Author ValidYN="Y"><LastName>Sankare</LastName><ForeName>Moussa Hama</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Horton</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Whately-Smith</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sow</LastName><ForeName>Samba Ousmane</ForeName><Initials>SO</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01586169</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>05</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Negl Trop Dis</MedlineTA><NlmUniqueID>101291488</NlmUniqueID><ISSNLinking>1935-2727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000871">Anthelmintics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>F4216019LN</RegistryNumber><NameOfSubstance UI="D015766">Albendazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Br J Ophthalmol. 2012 May;96(5):614-8</RefSource><PMID Version="1">22133988</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 2003 Sep;69(3):331-5</RefSource><PMID Version="1">14628953</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasitol Today. 1999 Sep;15(9):382-6</RefSource><PMID Version="1">10461168</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Pharmacol. 2002 Oct;42(10):1122-33</RefSource><PMID Version="1">12362927</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1992 Sep 24;327(13):921-5</RefSource><PMID Version="1">1325036</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Southeast Asian J Trop Med Public Health. 1995 Mar;26(1):124-7</RefSource><PMID Version="1">8525398</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2008;2(1):e171</RefSource><PMID Version="1">18235853</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bull World Health Organ. 1998;76(6):599-606</RefSource><PMID Version="1">10191556</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 2011 Aug;85(2):291-4</RefSource><PMID Version="1">21813850</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bull World Health Organ. 1997;75(6):491-503</RefSource><PMID Version="1">9509621</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Infect Dis Rep. 2007 Jan;9(1):21-8</RefSource><PMID Version="1">17254501</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 2007 Jun;76(6):1153-7</RefSource><PMID Version="1">17556628</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Parasitol. 1992 Jun;43(2):91-4</RefSource><PMID Version="1">1519031</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasitology. 2000;121 Suppl:S147-60</RefSource><PMID Version="1">11386686</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 1988 Jun 3;259(21):3150-3</RefSource><PMID Version="1">3285045</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2002 Aug 15;35(4):395-402</RefSource><PMID Version="1">12145722</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Parasitol. 2006 Jul;22(7):285-91</RefSource><PMID Version="1">16730230</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Antimicrob Agents. 2002 Mar;19(3):189-94</RefSource><PMID Version="1">11932140</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 2006 Apr;100(4):335-45</RefSource><PMID Version="1">16271272</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015766" MajorTopicYN="N">Albendazole</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000871" MajorTopicYN="N">Anthelmintics</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018890" MajorTopicYN="N">Chemoprevention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008302" MajorTopicYN="N" Type="Geographic">Mali</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058069" MajorTopicYN="N">Neglected Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014141" MajorTopicYN="N">Trachoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC3649960</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>07</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>04</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23675549</ArticleId><ArticleId IdType="doi">10.1371/journal.pntd.0002221</ArticleId><ArticleId IdType="pii">PNTD-D-12-01112</ArticleId><ArticleId IdType="pmc">PMC3649960</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B51 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001B51 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:23675549
|texte= A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:23675549" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |